Business
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a
About this update from Kymera Therapeutics, Inc.
[{"type":"image","alt":"Kymera Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kymera Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/c6ae18a40a38445654545584ae5e2b38"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dnIr_XVqx3Qx7MoOqux__g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3/https://media.zenfs.com/en/globenewswire.com/c6ae18a40a38445654545584ae5e2b38","width":300,"height":69},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/dnIr_XVqx3Qx7MoOqux__g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3/https://media.zenfs.com/en/globenewswire.com/c6ae18a40a38445654545584ae5e2b38","width":300,"height":69}},"lazy":false},{"type":"text","content":"Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases","length":198,"tagName":"p"},{"type":"text","content":"KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively","length":152,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its first-in-class, oral STAT6 degrader, will be featured in a late breaking oral presentation at the Society for Investigative Dermatology (SID) Annual Meeting being held May 13-16, in Chicago, IL, and an oral presentation at the American Thoracic Society (ATS) Respiratory Innovation Summit being held May 15-16, in Orlando, FL.","length":666,"tagName":"p"},{"type":"text","content":"“These presentations are an important opportunity for us to engage with the medical community and discuss the potential of KT-621 to expand patient access to a novel oral systemic therapy across a range of chronic immuno-inflammatory diseases, including atopic dermatitis and asthma, where treatment options remain limited,” said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. “The depth and consistency of the data we’ve r...